Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study.
Expert Rev Clin Pharmacol
; 16(9): 877-883, 2023.
Article
em En
| MEDLINE
| ID: mdl-37477611
ABSTRACT
BACKGROUND:
Histamine type-2-receptor antagonist drugs (H2-antagonists) have been used as standard treatment to prevent hypersensitivity reactions (HRs) in paclitaxel-containing regimens, however, their use has been strongly questioned. Ranitidine has been the most widely used H2-antagonist. Therefore, especially after its withdrawal from the market, the objective of this study is to determine the impact of its elimination from premedication on HR incidence.METHODS:
A cohort, multicenter, observational, prospective, and non-inferiority study, including paclitaxel-naïve cancer patients, designed to determine the incidence of HRs of any grade associated with paclitaxel administration and analyze non-inferiority against the incidence estimated in the literature (20%), with 5% as the maximum difference (Δ). Patients with a solid neoplasm of any type/stage, who initiated treatment with paclitaxel without H2-antagonists in the premedication regimen were enrolled.RESULTS:
A total of 441 patients were included, of whom 50 presented 54 HRs of any grade. The cumulative incidence was 11.3% (95%CI 8.5-14.7), thus fulfilling the hypothesis of non-inferiority. Of the overall HRs detected, 15 were grade ≥ 3 with a cumulative incidence of 3.4% (95%CI 1.9-5.5).CONCLUSIONS:
This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hipersensibilidade a Drogas
/
Neoplasias
/
Antineoplásicos Fitogênicos
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Clin Pharmacol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Espanha